SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales

Wern Brings Strong Team Building, Growth, and Sales Skills to SANUWAVE After a Career of Growing Start Ups Into Mid and Large Sized Companies

EDEN PRAIRIE, MN -- January 13, 2025 -- InvestorsHub NewsWire -- SANUWAVE Health, Inc. (the "Company" or " SANUWAVE ") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Timothy Wern as its Executive Vice President of Sales.

Wern brings deep experience in sales, team building, and funnel management from a career of progressive leadership roles at pioneering companies in healthcare, including HeartWare (acquired by Medtronic), Abiomed (acquired by Johnson & Johnson), and Ceevra Inc. His extensive background includes leading high-performing sales teams and successfully launching leading-edge medical devices in the U.S. and Canadian markets. His expertise spans sales management, strategic planning, and launching transformative technologies that improve patient outcomes.

Tim earned a Bachelor of Science in Economics from Cornell University, where he also played varsity baseball.

"We are pleased to welcome Tim to SANUWAVE," said CEO Morgan Frank. "He brings the experience and team building focus that will be instrumental to our ongoing plans to make SANUWAVE a leader in wound care."

"I'm excited to join SANUWAVE. The company is at a key inflection point and I'm eager to contribute my experience and energy to help accelerate its success. UltraMIST is one of the most exciting technologies I have seen and I look forward to collaborating with the talented team to drive the next phase of growth and positively impact patient outcomes," said Wern.

Tim began work at SANUWAVE on January 6, 2025.

About SANUWAVE

SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body's normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with supply chain and production constraints, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact: investors@Sanuwave.com

SANUWAVE Health (QB) (USOTC:SNWV)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025